In the present study we discovered that acquired IZI1551-resistance of mutBRAF and mutNRAS MM cells due to long-term exposure to the EC50 dose of IZI1551 coincides with an enhanced metastatic phenotype, and identified FAK to play a dual role in the observed phenotype-switch. Here, PTK2 is linked to Miyoshi myopathy.